The earnings call presented a strong quarter for Amicus Therapeutics with significant revenue growth and strategic advancements, particularly in Galafold and Pombiliti/Opfolda sales. Despite increased operating expenses and a decline in non-GAAP net income, the company's positive revenue trajectory, successful product launches, and advancements in their strategic partnership with Dimerix for DMX-200 highlight a positive outlook.

Company Guidance

During the Amicus Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided an optimistic guidance for the remainder of the year. They reported their 17th consecutive quarter of double-digit sales growth at constant exchange rates (CER), with Galafold achieving 13% year-over-year patient growth. The company projects that Galafold will reach its highest number of global patient starts this year. Additionally, they expect Pombiliti and Opfolda to achieve combined sales of $1 billion by the end of 2028, driven by a 50% to 65% growth at CER in 2025. Amicus also reiterated their confidence in achieving GAAP profitability in the second half of 2025. Furthermore, they announced the advancement of their strategic partnership with Dimerix and the DMX-200 compound, which is on track for full enrollment in the ACTION3 pivotal study by year-end. Overall, Amicus emphasized its strong financial discipline and strategic focus on expanding market reach and improving patient access, positioning the company for sustained growth well into the future.

Double-Digit Revenue Growth

Amicus delivered its 17th consecutive quarter of double-digit revenue growth at constant exchange rates, with a 22% increase in total revenue to $154.7 million over the same period in 2024.

Strong Galafold Performance

Galafold revenue reached $128.9 million this quarter, up 12% at constant exchange rates and 16% in reported terms, ending the quarter with over 69% global market share for treated Fabry patients with amenable mutations.

Pombiliti and Opfolda Sales Growth

Revenue for Pombiliti and Opfolda reached $25.8 million, up 58% at constant exchange rates, with strong sales growth driven by new launches in several countries.

Positive Financial Outlook

The company reiterated its expectation to achieve positive GAAP net income during the second half of 2025, reflecting strong financial discipline.

Advancement of DMX-200

The strategic partnership with Dimerix for DMX-200 in late-stage Phase III development for a rare kidney disease marked a key milestone with the ACTION3 pivotal study on track for full enrollment by year-end.

Amicus (FOLD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FOLD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.04 / -	-0.02	―	―	―
Jul 31, 2025	2025 (Q2)	-0.12 / -0.08	-0.05	-60.00% (-0.03)
May 01, 2025	2025 (Q1)	-0.05 / -0.07	-0.16	56.25% (+0.09)
Feb 19, 2025	2024 (Q4)	0.01 / 0.05	-0.11	145.45% (+0.16)
Nov 06, 2024	2024 (Q3)	<0.01 / -0.02	-0.07	71.43% (+0.05)
Aug 08, 2024	2024 (Q2)	-0.06 / -0.05	-0.15	66.67% (+0.10)
May 09, 2024	2024 (Q1)	-0.06 / -0.16	-0.18	11.11% (+0.02)
Feb 28, 2024	2023 (Q4)	-0.06 / -0.11	-0.19	42.11% (+0.08)
Nov 08, 2023	2023 (Q3)	-0.08 / -0.07	-0.12	41.67% (+0.05)
Aug 08, 2023	2023 (Q2)	-0.11 / -0.15	-0.21	28.57% (+0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FOLD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$6.13	$5.99	-2.28%
May 01, 2025	$7.68	$6.68	-13.02%
Feb 19, 2025	$9.85	$9.56	-2.94%
Nov 06, 2024	$11.74	$11.24	-4.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amicus Therapeutics (FOLD) report earnings?

Amicus Therapeutics (FOLD) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Amicus Therapeutics (FOLD) earnings time?

Amicus Therapeutics (FOLD) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FOLD EPS forecast?

FOLD EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing